Tag Archive for: Investment

Novo Holdings reports Total Income and Investment Returns of DKK 31 billion (€4.2 billion) for 2023. Total Assets grow by 38% to DKK 1,114 billion (€149 billion)

/in

Copenhagen, Denmark – Novo Holdings today announced its financial results for 2023*. Strong Investment Portfolio performance, and growth of the Novo Group companies drive Total Income and Investment Returns to DKK 31 billion (€4.2 billion) for 2023, up from DKK 3 billion (€0.4 billion) in 2022. The Investment Portfolio generated a return of 9.4%, compared to […]

Read more

Novo Nordisk Foundation awarded more than DKK 9.1 billion for purposes benefitting society in 2023

/in

Focusing its support on science, education, innovation and development initiatives, the Foundation’s overall ambition is to improve human and planetary health. In 2023, the Foundation awarded more than DKK 9.1 billion in philanthropic grants and investments and supported a total of 751 new projects. The Foundation’s activities are guided by the belief that science and […]

Read more

Curve Therapeutics raises £40.5 million to turbocharge discovery platform and advance breakthrough pipeline

/in

Series A financing led by Pfizer Ventures with new investors Columbus Venture Partners and British Patient Capital which join founding investor Advent Life Sciences and seed investor Epidarex Capital Goal to advance proprietary discovery platform and progress pipeline of assets addressing challenging cancer targets into the clinic Southampton, UK, 27 February 2023 – Curve Therapeutics […]

Read more

Novo Holdings invests in Manipal Hospitals, a leading private hospital chain in India

/in

COPENHAGEN and SINGAPORE, February 6 – Novo Holdings today announced its investment in Manipal Hospitals (‘Manipal’), which constitutes Novo Holding’s largest investment in Asia to date. Manipal Hospitals is among the top healthcare providers in India, providing comprehensive curative and preventive care for a multitude of patients within India and from around the globe. Read more…

Read more

NeoPhore raises an additional £9.6m (USD $12.2m) Series B financing extension to further progress drug discovery pipeline

/in

Italian investors, NEVA SGR, LIFTT and Simon Fiduciaria, join the existing syndicate Additional investment brings the total Series B financing to £31.1 million (approx. USD $39.5 million) London, UK, 1 February 2024 – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces a further extension of £9.6m (approx. USD $12.2m) to its Series B […]

Read more